DTP Branches And Staff
Office of the Associate Director (OAD)
Jerry M. Collins, Ph.D., Associate Director, Shady Grove 4W614
James A. Crowell, Ph.D., Deputy Associate Director, Shady Grove 4W614
OAD provides planning, implementation, and oversight for all DTP activities, including participation in the NCI Experimental Therapeutics (NExT) initiative and the NCI-60 cell line testing program.
- Methodology of the In Vitro Cancer Screen
- Recent Changes in the Operation of the IVCLSP
Contracts Operations Branch (GCOB)
Chief - Dr. Mary K. Wolpert, Shady Grove 4W224
GCOB resides in a unique situation in relation to the extramural grant community and DTP's drug discovery and development activities. Through management of a large grant and cooperative agreement portfolio, GCOB staff maintains extensive interactions with the external research community and can provide advice to foster DTP's drug discovery mandate. Such activities include assisting grantees to access the NCI drug and Natural Product repositories, inviting scientists to participate in a DTP seminar series, and arranging for characterization of molecular targets in the 60-cell line screen. Staff can advise grantees regarding availability of NCI resources for development of their agents to clinical trial.
and Chemistry Branch (DSCB)
Chief - Dr. Joel Morris, 9609 Medical Center Drive, Rockville, MD
DSCB is responsible for the following activities in support of the discovery and development of novel anti-cancer agents: worldwide scientific liaison activities with universities and industries to stimulate the submission of a wide variety of synthetic compounds, and pure natural products for in vitro anti-cancer screening; management of the storage, inventory, documentation, synthesis, acquisition and distribution of chemical samples for research purposes to NIH and external investigators.
Natural Products Branch
Chief - Dr. David J. Newman, FNLCR, Riverside B
The primary responsibility of NPB is the acquisition of crude natural product materials from terrestrial and marine environments, usually via competitive contracts worldwide, for extraction and screening of extracts in the NCI cancer cell line screen. Extracts are distributed to qualified organizations worldwide for testing against any human disease, subject to the signing of a Material Transfer Agreement recognizing the rights of the source countries. NPB is also establishing collaborative programs through the signing of a Memorandum of Understanding with qualified research organizations in source countries for the screening of natural product extracts for anti-tumor activity, and for the preclinical and clinical development of active agents meeting NCI selection criteria. Other responsibilities are the oversight of operations of the Natural Products Repository and the Natural Products Extraction Laboratory.
Resources Branch (PRB)
Chief - Dr. B. Rao Vishnuvajjala, Shady Grove 4W102
PRB's goal is to provide DTP and the clinical research community with high-quality and well-characterized chemical substances and drug products. Whenever possible, USP/NF grade excipients with a proven track record for consistency and safety are used. The clinical supplies PRB provides are guaranteed to meet or exceed FDA accepted potency and purity requirements while in use. The end use stability studies are designed to provide maximum comfort to the patients and convenience for the health care professionals. PRB contract resources generally are used for drug candidates selected for clinical development. PRB becomes involved when drug candidates are approved by either the Drug Development Group.
Chief - Melinda G. Hollingshead, D.V.M., Ph.D., FNLCR Bldg 1043/11
BTB operates out of the National Cancer Institute at Frederick (NCI-Frederick), providing budgetary oversight and technical direction for an extensive contractual effort designed to discover chemotherapeutic agents for cancer and AIDS. Specifically, BTB's mission is five-fold: 1) to plan, direct, and implement a contract-supported program to screen compounds for indication of clinical efficacy in vivo; 2) to develop new screening models; 3) to produce, provide quality control for, and distribute to NCI, NIH, and the grantee community genetically and biologically defined rodents; 4) to maintain a repository of experimental animal and human tumor cell lines for use in research performed by the program and other qualified investigators; and 5) to define and publish biological testing screening protocols.
Pharmacology Branch (T&PB)
Chief - Myrtle Davis, D. V. M., Ph.D, Shady Grove 4W110
The primary responsibility of T&PB is to obtain the toxicology and pharmacology data necessary for NCI to file an Investigational New Drug (IND) application with the FDA in order to conduct Phase I clinical trials of new oncolytic agents in humans. To accomplish this goal, T&PB, through its network of contractors, determines or develops analytical methods for quantifying drug levels in biological fluids and tissues, plasma drug distribution and elimination kinetics in animal models, plasma protein binding and stability, metabolic potential, and maximum tolerated doses (MTD) and dose-limiting toxicities (DLT) in preliminary range-finding and IND-directed toxicology studies.
Technology Branch (ITB)
Chief - Dr. Daniel Zaharevitz, Shady Grove 4W134
ITB is the primary automated resource of information and data within DTP. ITB manages chemical and biological databases to support DTP's ongoing research efforts. ITB employs state-of-art software and hardware facilities to provide support for DTP and engages in collaborative research to promote further implementation of information technology within the branch.
Molecular Pharmacology Branch (MPB)
Chief - Dr. Beverly Teicher, Shady Grove 4W602
MPB is the organizational component of DTP that is responsible for developing and conducting screens directed toward identifying improved therapies for recalcitrant, rare and neglected cancers and participating as needed in the NExT Discovery program. MPB is the home of the classic NCI60 cell line screen. MPB runs the NCI60 cell line screen as a service available to the global cancer community where investigators can submit compounds and biologics for testing in this well validated resource. MPB can also provide investigators with frozen pellets, DNA and RNA from the NCI60 cell lines for their specific studies.
Resources Branch (BRB)
Chief - Dr. Stephen P. Creekmore, FNLCR, ATRF
The BRB supports preclinical and early (e.g., Phase I) clinical studies of biological response modifiers (BRMs) research in the biomedical community through a program of grants and contracts. These studies assess the effects of novel biological agents and explore relationships of biological responses with anti-tumor activity. An NCI Preclinical Repository distributes selected agents for peer-reviewed preclinical studies performed by both extramural and intramural investigators. Other contracts support the production and in vivo evaluation of monoclonal antibodies, immunoconjugates, and other biologicals.
BRB program staff oversee the Biopharmaceutical Development Program (BDP) at the Frederick Cancer Research and Development Center (FCRDC). BDP produces a variety of biopharmaceuticals under current Good Manufacturing Practices (cGMP) for Phase I/II human clinical trials or advanced preclinical animal testing. BDP is operated under contract by Science Applications International Corporation (SAIC) Frederick, which provides operations and technical support to FCRDC.